815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Giftify received a Nasdaq notice on March 24, 2026, stating its closing bid price had been below the $1 minimum for 30 consecutive business days. The company has 180 calendar days to regain compliance, and Nasdaq could grant an additional 180 days if the company qualifies, which could require a reverse stock split. If Nasdaq concludes the deficiency cannot be cured, shares would be subject to delisting.
Nasdaq notice dated March 24, 2026, cites Listing Rule 5550(a)(2), the $1 minimum bid price requirement.
Closing bid price failed to meet $1 for the last 30 consecutive business days.
Company has 180 calendar days to regain compliance by closing at or above $1 for at least 10 consecutive business days.
Company may be eligible for a second 180-day period and may need a reverse stock split; failure to cure could lead to delisting notice.
Village Super Market disclosed that Wakefern Food Corp. filed counterclaims in the ongoing New Jersey litigation, seeking a declaration that good cause exists under Wakefern's By-Laws to compel the company to sell its Wakefern stock and exit the cooperative. The company says the claims are frivolous, that Wakefern has not alleged a board vote on the matter, and that the dispute has not materially affected operations or financial performance so far, though it cannot assess the probability of outcome or range of possible loss.
On March 19, 2026, Wakefern filed an answer, counterclaims and a third-party complaint in the Law Division, Middlesex County, Superior Court of New Jersey.
Counterclaims seek a declaration that good cause exists under Wakefern By-Laws to compel the company to sell its Wakefern stock and exit the cooperative.
The company says Wakefern has not alleged a Wakefern board vote required under its By-Laws and that it has no knowledge of such action.
The company intends to seek dismissal of Wakefern's claims and cannot determine the probability of outcome or range of reasonably possible loss.
Hub Group received a Nasdaq notice on March 19, 2026, because it has not timely filed its 2025 annual report on Form 10-K. The notice has no immediate effect on the listing or trading of its Class A common stock, but the company must submit a compliance plan by May 18, 2026, and Nasdaq can grant until September 14, 2026 to regain compliance. The company attributes the delay to a restatement of its 2025 quarterly financial statements, which matters to shareholders because the filing has not yet been completed.
Nasdaq notice received March 19, 2026, under Listing Rule 5250(c)(1) for not timely filing the 2025 Form 10-K
Compliance plan due to Nasdaq by May 18, 2026; Nasdaq may grant an exception until September 14, 2026
March 23, 2026 amendment to the June 20, 2025 credit agreement extends the deadline for delivering financial statements and waives related defaults
Delay tied to restatement of first, second and third quarter 2025 financial statements; company is also assessing impact on 2024 and 2023 statements
On March 18, 2026, PGE received final Oregon Public Utility Commission orders approving $110 million of recovery for deferred 2024 and January 2024 storm costs, against $124 million requested before interest. PGE expects a $15 million pre-tax GAAP charge in the first quarter of 2026, which it plans to exclude from adjusted earnings and 2026 adjusted earnings guidance. On March 23, 2026, PGE also entered credit agreements for a $350 million unsecured term loan and a delayed draw term loan of up to $681 million to help fund the purchase of assets from PacifiCorp.
OPUC final orders received March 18, 2026 approve $110 million in recovery against $124 million requested, before interest
PGE expects a $15 million pre-tax GAAP charge in Q1 2026 and plans to exclude it from adjusted earnings and 2026 adjusted guidance
$350 million unsecured term loan with borrowings available through September 23, 2026 and maturity on March 23, 2028
Delayed draw term loan of up to $681 million to finance assets purchased from PacifiCorp, with maturity 364 days after funding
The U.S. Attorney's Office for the Southern District of New York unsealed an indictment of three individuals associated with Super Micro Computer over an alleged conspiracy to commit export-control violations. The company is not named as a defendant and says it is cooperating fully with the government's investigation. One of the charged individuals, board member and Senior Vice President of Business Development Yih-Shyan "Wally" Liaw, resigned from the board effective March 20, 2026.
Indictment of three individuals announced March 19, 2026; Super Micro is not named as a defendant
Yih-Shyan "Wally" Liaw resigned from the Board of Directors effective March 20, 2026, not due to a disagreement with the company
Two employees placed on administrative leave and the contractor relationship terminated, effective immediately
DeAnna Luna appointed acting Chief Compliance Officer; the board now has eight directors
Cryo-Cell International received a March 9, 2026 notice from NYSE American stating it does not meet Section 1003(a) of the NYSE American Company Guide, citing a stockholders' deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The notice has no immediate effect on trading, and the company plans to submit a compliance plan by April 8, 2026, but there is no assurance NYSE American will accept the plan or that compliance will be regained.
NYSE American notice received March 9, 2026, under Section 1003(a) of the Company Guide
Cited a stockholders' deficit as of November 30, 2025, and net losses in two of the three fiscal years ended November 30, 2023, 2024 and 2025
Common stock continues to trade as CCEL; compliance plan due by April 8, 2026; if accepted, the company is typically granted up to 18 months from receipt of the notice
Agape ATP Corp said Nasdaq informed it on March 10, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. As a result, the Hearings Panel hearing set for March 17, 2026 was cancelled, and the company's common stock will continue to trade on Nasdaq. The change removes the delisting process that had been underway for shareholders.
Nasdaq notified the company on January 27, 2026 that it was not in compliance with the $1.00 minimum bid price rule.
On February 2, 2026, Nasdaq staff determined to delist the securities after the closing bid was $0.10 or less for ten consecutive trading days as of January 30, 2026.
On March 10, 2026, Nasdaq's Hearings Advisor confirmed the company had regained bid price compliance.
The hearing scheduled for March 17, 2026 was cancelled, and the stock will continue to trade under the symbol ATPC.
On March 6, 2026, Iveda Solutions received a Nasdaq letter stating its common stock failed to maintain a minimum bid price of $1 per share over the last 30 consecutive business days, a breach of Nasdaq Rule 5550(a)(2). The notice has no immediate effect on the listing, and the company has until September 2, 2026 to regain compliance, after which Nasdaq could begin delisting proceedings if it has not.
Nasdaq letter dated March 6, 2026 cites closing bid price below $1 for 30 consecutive business days
Compliance period of 180 calendar days runs until September 2, 2026
Regaining compliance requires a closing bid price of at least $1 for ten consecutive business days
If not compliant by the deadline, the company could face delisting, with the right to appeal to a Nasdaq Hearings Panel
Moderna and Arbutus/Genevant agreed on March 3, 2026 to settle all pending patent infringement litigation between them, covering Spikevax and mRESVIA, with no future royalties owed. Moderna must pay a $950 million lump sum by July 8, 2026, and may owe a further $1.3 billion contingent payment depending on a Federal Circuit appeal over whether 28 U.S.C. § 1498 bars the claims; if Moderna prevails, no further payments are due.
$950 million noncontingent lump sum payment due on or before July 8, 2026
Contingent payment of $1.3 billion, due within 90 days of a Federal Circuit decision, if § 1498 does not bar the claims
Moderna may appeal the § 1498 issue to the Federal Circuit; full prevailing outcome means no further payments
Fully paid-up, royalty-free license covers Spikevax, mNEXSPIKE and mRESVIA; full agreement to be filed with the Form 10-Q for the quarter ending March 31, 2026
Genevant and Arbutus, both tied to Roivant, agreed to settle their patent infringement litigation against Moderna over LNP technology in its COVID-19 vaccines. Moderna will pay $950 million by July 8, 2026, plus a contingent $1.3 billion tied to a Federal Circuit appeal on 28 U.S.C. §1498. Roivant's board also raised its share repurchase authorization to $1.0 billion, including the previously approved $500 million.
Moderna to pay a noncontingent $950 million lump sum on or before July 8, 2026
Additional $1.3 billion contingent payment depends on the Federal Circuit's §1498 ruling; a partial outcome yields a prorated amount
Board increased the share repurchase program to up to $1.0 billion, funded with cash on hand, with no expiration date
Century Aluminum said its previously issued financial statements for fiscal 2023 and 2024 and several 2024-2025 interim periods should no longer be relied upon. The restatement stems from a change to fully consolidate its Jamalco production assets, after SEC staff disagreed with the company's view that the change was immaterial. The company said the change does not affect net income attributable to Century stockholders, but it expects to report a material weakness in internal controls.
Affected periods include fiscal years ended December 31, 2023 and 2024, and interim periods through September 30, 2025.
2024 gross profit as restated is $172.0 million, down from $185.0 million as previously reported; 2023 gross profit is $87.6 million, down from $91.9 million.
Total assets at December 31, 2024 rise to $2,120.0 million from $1,939.4 million; net income attributable to Century stockholders is unchanged.
The Audit Committee made the conclusion on March 2, 2026, and the company expects a material weakness in internal controls.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.